Decentralized Rapid Diagnostics
“As the number of positive cases increases, there has also been a surge in testing that is beginning to hit limitations on scale. Contributing factors include limitations on consumable supplies (for example, reagents) for both lab-based and rapid point-of-care molecular testing, the overall turnaround times for lab results, and capacity for lab-based molecular testing. Pooled testing has recently been given an Emergency Use Authorization from the US Food and Drug Administration as an option for improving capacity for lab-based molecular testing. Dependence on such testing for proactive monitoring is likely limited. Expansion for rapid point-of-care molecular testing will likely prove to be fruitful for monitoring purposes.” (Shifting focus to a comprehensive COVID-19-monitoring infrastructure, McKinsey & Company, August 2020).
NAOR is a rapid isothermal RNA diagnostic platform, initially addressing SARS-CoV-2 virus, the virus strain that causes COVID-19. The platform brings rapid high throughput, lab-grade detection to the field (schools, airports and airplanes, borders, workplace) and to at-home settings. Our platform is intended to provide a comprehensive solution for a variety of settings that organizations and countries of different sizes are facing, enabling a faster and safer path to open up their respective economy.